Novartis received approval from the FDA for Exforge, a once-daily tablet combination of two high blood pressure medicines: Diovan, an angiotensin receptor blocker, and Norvasc, a calcium channel blocker. The approval was supported by an extensive clinical program involving more than 5,000 patients. In two placebo-controlled trials, Exforge helped nine out of 10 patients reach their treatment goal of diastolic blood pressure under 90 mmHg, or more than a 10 mmHg reduction in diastolic blood ...